Acquired Company

Syncona acquired Freeline Therapeutics Holdings plc on 11/22/2023 for $6.50 per American Depositary Share in an all-cash transaction, valuing Freeline's entire issued share capital at approximately $28.3 million.

Freeline Therapeutics Holdings PLC operates as a biotechnology company. The Company focuses on developing liver directed gene therapies for bleeding disorders and other debilitating chronic diseases. Freeline Therapeutics serves patients worldwide. Show more

Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom

www.freeline.life

Biological Product (except Diagnostic) Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$6.48

Open

$6.48

Volume

N/A

Day Range

$6.48 - $6.48

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

1.10%

Institutional Own.

45.88%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FLT201 Details Genetic disorder, Gaucher disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FLT180a (AAVS3 capsid) Details Hemophilia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FLT190 Details Genetic disorder, Fabry disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.